CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), returns to Stock Day to give a detailed update on status of clinical trials for Pro 140, fast tracking with the FDA for final approval, and hopes to bring to market by 2020.

OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # patient safety # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies